Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Does comorbid depression and anxiety portend poor long-term outcomes following surgery for lumbar spondylolisthesis? Five-year analysis of the Quality Outcomes Database
DiDomenico, Joseph D., Virk, Michael S., Godzik, Jakub , Johnson, Sarah E. , Bydon, Mohamad , Mummaneni, Praveen V. , Bisson, Erica F. , Glassman, Steven D. , Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Shaffrey, Christopher I., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Knightly, John J. , Shaffrey, Mark E., Slotkin, Jonathan R., Haid, Regis W., Turner, Jay D. , Farber, Samuel Harrison , Virk, Michael S., Shaffrey, Christopher I. , Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | September 7, 2024 | Volume: 41 | Issue: 5 | Pages: 579-588

10.3171/2024.5.spine24325 | PMID 39241264 Get It

OBJECTIVE Depression and anxiety are associated with poor outcomes following spine surgery. However, the influence of these conditions on achieving a minimal clinically important difference (MCID) following lumbar spine surgery, as well as the potential compounding effects of comorbid depression and anxiety, is not well understood. This study explores the impact of comorbid depression and anxiety on long-term clinical outcomes following surgical treatment for degenerative lumbar spondylolisthesis. METHODS This study was a retrospective analysis of the multicenter, prospectively collected Quality Outcomes Database (QOD). Patients with surgically treated grade 1 lumbar spondylolisthesis from 12 centers were included. Preoperative baseline characteristics and comorbidities were recorded, including self-reported depression and/or anxiety. Pre- and postoperative patient-reported outcomes (PROs) were recorded: the numeric rating scale (NRS) score for back pain (NRS-BP), NRS score for leg pain (NRS-LP), Oswestry Disability Index (ODI), and EQ-5D. Patients were grouped into 3 cohorts: no self-reported depression or anxiety (non-SRD/A), self-reported depression or anxiety (SRD/A), or presence of both comorbidities (SRD+A). Changes in PROs over time, satisfaction rates, and rates of MCID were compared. A multivariable regression analysis was performed to establish independent associations. RESULTS Of the 608 patients, there were 452 (74.3%) with non-SRD/A, 81 (13.3%) with SRD/A, and 75 (12.3%) with SRD+A. Overall, 91.8% and 80.4% of patients had ≥ 24 and ≥ 60 months of follow-up, respectively. Baseline PROs were universally inferior for the SRD+A cohort. However, at 60-month follow-up, changes in all PROs were greatest for the SRD+A cohort, resulting in nonsignificant differences in absolute NRS-BP, NRS-LP, ODI, and EQ-5D across the 3 groups. MCID was achieved for the SRD+A cohort at similar rates to the non-SRD/A cohort. All groups achieved > 80% satisfaction rates with surgery without significant differences across the cohorts (p = 0.79). On multivariable regression, comorbid depression and anxiety were associated with worse baseline PROs, but they had no impact on 60-month PROs or 60-month achievement of MCIDs. CONCLUSIONS Despite lower baseline PROs, patients with comorbid depression and anxiety achieved comparable rates of MCID and satisfaction after surgery for lumbar spondylolisthesis to those without either condition. This quality-of-life benefit was durable at 5-year follow-up. These data suggest that patients with self-reported comorbid depression and anxiety should not be excluded from consideration of surgical intervention and often substantially benefit from surgery.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Jhaveri, Komal , Lim, Elgene , Jeselsohn, Rinath , Cynthia, X. , Hamilton, Erika , Osborne, Cynthia R. , Bhave, Manali Ajay, Kaufman, Peter A. , Beck, J. Thaddeus , Manso, Luís , Parajuli, Ritesh , Wang, Hwei-Chung, Tao, Jessica J. , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean‐Yves , Lu, Yen‐Shen , Larson, Timothy , Jerez, Yolanda , Sohn, Joohyuk , Saura, Cristina , Bardia, Aditya , Sammons, Sarah , Bacchion, Francesca , Li, Yujia , Estrem, Shawn T. , Nguyen, Bastien , Ismail‐Khan, Roohi , Smyth, Lillian M. , Beeram, Muralidhar , Jhaveri, Komal L , Ma, Cynthia , Hamilton, Erika P , Manso Sanchez, Luis , Im, Seock-Ah , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean-Yves , Lu, Yen-Shen , Larson, Timothy , Sideras, Kostandinos , Sohn, Joohyuk , Kim, Sung-Bae , Saura, Cristina , Bardia, Aditya , Sammons, Sarah L , Li, Yujia , Nguyen, Bastien , Ismail-Khan, Roohi , Smyth, Lillian , Beck, Joseph T , Im, Seock‐Ah , Sideras, Kostandinos , Yuen, Eunice , Rodrik-Outmezguine, Vanessa S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2024 | Volume: 42 | Issue: 35 | Pages: 4173-4186

10.1200/jco.23.02733 | PMID 39241211 Get It

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1- mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2–negative (HER2–) ABC experience is reported here. METHODS An i3+3 dose-escalation design was used, followed by dose expansions of imlunestrant as monotherapy or in combination with abemaciclib with or without aromatase inhibitor (AI), everolimus, or alpelisib. Imlunestrant was administered orally once daily and with the combination partner per label. RESULTS Overall, 262 patients with ER+/HER2– ABC were treated (phase Ia, n = 74; phase Ib, n = 188). Among patients who received imlunestrant monotherapy (n = 114), no dose-limiting toxicities or discontinuations occurred. At the RP2D (400 mg once daily), patients (n = 51) reported grade 1-2 nausea (39.2%), fatigue (39.2%), and diarrhea (29.4%). Patients at RP2D had received previous cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; 92.2%), fulvestrant (41.2%), and chemotherapy (29.4%) for ABC and achieved a median progression-free survival (mPFS) of 7.2 months (95% CI, 3.7 to 8.3). Among patients who received imlunestrant + abemaciclib (n = 42) and imlunestrant + abemaciclib + AI (n = 43), most (69.4%) were treatment-naïve for ABC; all were CDK4/6i-naïve. Patients treated with imlunestrant + everolimus (n = 42)/alpelisib (n = 21) had received previous CDK4/6i (100%), fulvestrant (34.9%), and chemotherapy (17.5%) for ABC. No new safety signals or interactions with partnered drugs were observed. The mPFS was 19.2 months (95% CI, 13.8 to not available) for imlunestrant + abemaciclib and was not reached for imlunestrant + abemaciclib + AI. The mPFS with imlunestrant + everolimus/alpelisib was 15.9 months (95% CI, 11.3 to 19.1)/9.2 months (95% CI, 3.7 to 11.1). Antitumor activity was evident regardless of ESR1 mutation status. CONCLUSION Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2– ABC.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary, Nadine J. , Merle, James L. , Richardson, Joshua E. , Garcia, Sofia F. , Tesch, Nathan , DiMartino, Lisa , Hassett, Michael J. , Cella, David , Smith, Justin D. , Kroner, Barbara L, Ruddy, Kathryn, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Cahue, September, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Faris, Nicolas, Flores, Anne Marie, Garcia, Martha, Hodgdon, Christine, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearson, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Richardson, Kimberly, Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tramontano, Angela C. , Wong, Sandra , Cella, David , Garcia, Sofia F , Bass, Michael , Cheville, Andrea , Mitchell, Sandra A , Jensen, Roxanne E. , Minteer, Sarah A. , Austin, Jessica D. , Osarogiagbon, Raymond U. , Wong, Sandra L. , Schrag, Deborah , Smith, Ashley Wilder , Kroner, Barbara L, Griffin, Joan M. , Ruddy, Kathryn J. , Ardini, Mary-Anne , Barrett, Fiona, Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Popovic, Jennifer R. , Preiss, Liliana , Reich, James, Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JAMIA Open | September 5, 2024 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooae081 | PMID 39234146 Get It

AbstractObjectivesTo report lessons from integrating the methods and perspectives of clinical informatics (CI) and implementation science (IS) in the context of Improving the Management of symPtoms during and following Cancer Treatment (IMPACT) Consortium pragmatic trials.Materials and MethodsIMPACT informaticists, trialists, and implementation scientists met to identify challenges and solutions by examining robust case examples from 3 Research Centers that are deploying systematic symptom assessment and management interventions via electronic health records (EHRs). Investigators discussed data collection and CI challenges, implementation strategies, and lessons learned.ResultsCI implementation strategies and EHRs systems were utilized to collect and act upon symptoms and impairments in functioning via electronic patient-reported outcomes (ePRO) captured in ambulatory oncology settings. Limited EHR functionality and data collection capabilities constrained the ability to address IS questions. Collecting ePRO data required significant planning and organizational champions adept at navigating ambiguity.DiscussionBringing together CI and IS perspectives offers critical opportunities for monitoring and managing cancer symptoms via ePROs. Discussions between CI and IS researchers identified and addressed gaps between applied informatics implementation and theory-based IS trial and evaluation methods. The use of common terminology may foster shared mental models between CI and IS communities to enhance EHR design to more effectively facilitate ePRO implementation and clinical responses.ConclusionImplementation of ePROs in ambulatory oncology clinics benefits from common understanding of the concepts, lexicon, and incentives between CI implementers and IS researchers to facilitate and measure the results of implementation efforts.
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary
Kasi, Pashtoon Murtaza , Ma, Li , Hart, Lowell L., Wong, Jenna , Spigel, David R. , Schnabel, Catherine A. , Reeves, James A. , Hálfdánarson, Þorvarður R. , Treuner, Kai , Greco, Frank A. , Fuentes, Harry E , Kasi, Pashtoon Murtaza , Spigel, David R , Halfdanarson, Thorvardur R , Treuner, Kai , Greco, F Anthony , Fuentes, Harry E , Wong, Jenna

Mayo Clinic

JCO Precision Oncology | September 4, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00191 | PMID 39231374 Get It

PURPOSE Cancer of unknown primary (CUP) is a syndrome comprising metastatic cancers without a clinically identified primary site. Although patients with CUP have an unfavorable prognosis, treatment with site-specific therapies guided by clinical features, standard pathology, and molecular assays can improve overall survival. The 92-gene assay (CancerTYPE ID) is a gene expression–based classifier that helps identify the tissue of origin for metastatic cancers with unknown or uncertain diagnoses. This study reports the frequency of selected molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF, in patients with CUP in the MOSAIC database to highlight potential treatment options. METHODS MOSAIC is a database of patients with CUP submitted for CancerTYPE ID testing and NeoTYPE biomarker testing. Tumor biopsy samples were analyzed by CancerTYPE ID for tumor type identification and further tested for molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF. RESULTS CancerTYPE ID identified a specific tumor type in 92.5% (2,929 of 3,168) of CUP cases in the MOSAIC database. The most commonly identified histological type was adenocarcinoma (75.4%), with pancreaticobiliary being the most common molecularly diagnosed cancer (24.9%). Aberrations in KRAS, IDH1/2, BRCA, and BRAF genes were identified in 18.8% (n = 597) of biopsies. A cancer-specific US Food and Drug Administration (FDA)–approved or investigational targeted therapy was potentially available for 24.6% (n = 147) of these patients. CONCLUSION This retrospective analysis supports incorporating CancerTYPE ID into the evaluation for patients with CUP to help determine the tissue of origin and identify actionable genetic alterations. This approach may allow more patients with CUP to benefit from site-specific FDA-approved targeted therapies or enrollment into clinical trials.
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research
Miller, Melanie J. , Diaz, Adam , Conti, Catherine , Albala, Bruce, Flenniken, Derek , Fockler, Juliet , Kwang, Winnie, Sacrey, Diana Truran, Ashford, Miriam T. , Skirrow, Caroline , Weston, Jack , Fristed, Emil , Farias, Sarah Tomaszewski , Korecka, Magda, Wan, Yang , Aisen, Paul, Harvey, Danielle, Petersen, Ronald C. , Okonkwo, Ozioma C. , Weiner, Michael W., Nosheny, Rachel L. , Initiative, Alzheimer's Disease Neuroimaging, Harvey, Danielle , Harvey, Danielle J , Beckett, Laurel , Harvey, Danielle, Lee, Edward B. , Li, Yi‐Ju , Mindt, Mónica Rivera , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 2, 2024 | Volume: 20 | Issue: 10 | Pages: 7232-7247

10.1002/alz.14234 | PMID 39219153 Get It

AbstractINTRODUCTIONWe evaluated preliminary feasibility of a digital, culturally‐informed approach to recruit and screen participants for the Alzheimer's Disease Neuroimaging Initiative (ADNI4).METHODSParticipants were recruited using digital advertising and completed digital surveys (e.g., demographics, medical exclusion criteria, 12‐item Everyday Cognition Scale [ECog‐12]), Novoic Storyteller speech‐based cognitive test). Completion rates and assessment performance were compared between underrepresented populations (URPs: individuals from ethnoculturally minoritized or low education backgrounds) and non‐URPs.RESULTSOf 3099 participants who provided contact information, 654 enrolled in the cohort, and 595 completed at least one assessment. Two hundred forty‐seven participants were from URPs. Of those enrolled, 465 met ADNI4 inclusion criteria and 237 evidenced possible cognitive impairment from ECog‐12 or Storyteller performance. URPs had lower ECog and Storyteller completion rates. Scores varied by ethnocultural group and educational level.DISCUSSIONPreliminary results demonstrate digital recruitment and screening assessment of an older diverse cohort, including those with possible cognitive impairment, are feasible. Improving engagement and achieving educational diversity are key challenges.Highlights A total of 654 participants enrolled in a digital cohort to facilitate ADNI4 recruitment. Culturally‐informed digital ads aided enrollment of underrepresented populations. From those enrolled, 42% were from underrepresented ethnocultural and educational groups. Digital screening tools indicate > 50% of participants likely cognitively impaired. Completion rates and assessment performance vary by ethnocultural group and education.
Effect of endothelin‐1 on the blood pressure response to acute hypoxia and hyperoxia in healthy young men
Gonsalves, Anna M. , Baker, Sarah , Jacob, Dain W. , Limberg, Jacqueline K. , Limberg, Jacqueline K , Harper, Jennifer L. , Manrique‐Acevedo, Camila

Mayo Clinic

Physiological Reports | September 2, 2024 | Volume: 12 | Issue: 17 | Pages: No page available

10.14814/phy2.70004 | PMID 39218615 Get It

AbstractEndothelin‐1 (ET‐1) and its receptors are linked to increases in sensitivity of the chemoreceptors to hypoxic stress and the development of hypertension in preclinical models. We hypothesized ET receptor antagonism would lower resting blood pressure (BP) as well as the acute BP response to chemoreflex stress. Twenty‐four men (31 ± 5 years, 26 ± 3 kg/m2) completed two study visits (control, bosentan). On each visit, BP was assessed under three conditions: (1) normoxia (FiO2 0.21), (2) chemoreflex excitation via hypoxia (FiO2 0.05–0.21), (3) chemoreflex inhibition via hyperoxia (FiO2 1.00). Bosentan increased plasma ET‐1 (0.94 ± 0.90 to 1.27 ± 0.62 pg/mL, p = 0.004), supporting receptor blockade. Resting diastolic (73 ± 5 to 69 ± 7 mmHg, p = 0.007) and mean (93 ± 7 to 88 ± 7 mmHg, p = 0.005) BP were reduced following bosentan compared to control with no change in systolic BP (p = 0.507). The mean BP response to both acute hypoxia (−0.48 ± 0.38 to −0.25 ± 0.31 mmHg/%, p = 0.004) and hyperoxia (area under the curve −93 ± 108 to −27 ± 66 AU, p = 0.018) were attenuated following bosentan. Acute ET receptor inhibition attenuates the rise in BP during chemoreflex excitation as well as the fall in BP during chemoreflex inhibition in healthy young men. These data support a role for ET‐1 in control of resting BP, possibly through a chemoreceptor‐mediated mechanism.
Predictors of patient satisfaction after surgery for grade 1 degenerative spondylolisthesis: a 5-year analysis of the Quality Outcomes Database
Dru, Alexander, Johnson, Sarah E. , Linzey, Joseph R. , Foley, Kevin T. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Shaffrey, Mark E., Weaver, Jason, Bydon, Mohamad , Chou, Dean , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S. , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 31, 2024 | Volume: 41 | Issue: 5 | Pages: 658-665

10.3171/2024.5.spine24227 | PMID 39213671 Get It

OBJECTIVE Lumbar decompression and/or fusion surgery is a common operation for symptomatic lumbar spondylolisthesis refractory to conservative management. Multiyear follow-up of patient outcomes can be difficult to obtain but allows for identification of preoperative patient characteristics associated with durable pain relief, improved functional outcome, and higher patient satisfaction. METHODS A query of the Quality Outcomes Database (QOD) low-grade spondylolisthesis module for patients who underwent surgery for grade 1 lumbar spondylolisthesis (from July 2014 to June 2016 at the 12 highest-enrolling sites) was used to identify patient satisfaction, as measured with the North American Spine Society (NASS) questionnaire, which uses a scale of 1–4. Patients were considered satisfied if they had a score ≤ 2. Multivariable logistic regression was performed to identify baseline demographic and clinical predictors of long-term satisfaction 5 years after surgery. RESULTS Of 573 eligible patients from a cohort of 608, patient satisfaction data were available for 81.2%. Satisfaction (NASS score of 1 or 2) was reported by 389 patients (83.7%) at 5-year follow-up. Satisfied patients were predominantly White and ambulation independent and had lower baseline BMI, lower back pain levels, lower Oswestry Disability Index (ODI) scores, and greater EQ-5D index scores at baseline when compared to the unsatisfied group. No significant differences in reoperation rates between groups were reported at 5 years. On multivariate analysis, patients who were independently ambulating at baseline had greater odds of long-term satisfaction (OR 1.12, p = 0.04). Patients who had higher 5-year ODI scores (OR 0.99, p < 0.01) and were uninsured (OR 0.43, p = 0.01) were less likely to report long-term satisfaction. CONCLUSIONS Lumbar surgery for the treatment of grade 1 spondylolisthesis can provide lasting pain relief with high patient satisfaction. Baseline independent ambulation is associated with a higher long-term satisfaction rate after surgery. Higher ODI scores at 5-year follow-up and uninsured status are associated with lower postoperative long-term satisfaction.
Utilization of an artificial intelligence–enhanced, web‐based application to review bile duct brushing cytologic specimens: A pilot study
Marya, Neil B. , Powers, Patrick, Bois, Melanie C. , Hartley, Christopher , Kerr, Sarah E. , Thangaiah, Judith Jebastin, Cantley, Richard , Gleeson, Ferga C. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Levy, Michael J. , Jebastin, Judith A S , Cantley, Richard , Law, Ryan J, Maleki, Zahra , Pantanowitz, Liron , Petersen, Bret, Marya, Neil B. , Hartley, Christopher P , Norton, Daniel, Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Gores, Gregory J. , Maleki, Zahra , Petersen, Bret T. , Storm, Andrew C. , Graham, Rondell P.

Mayo Clinic

Cancer Cytopathology | August 29, 2024 | Volume: 132 | Issue: 12 | Pages: 779-787

10.1002/cncy.22898 | PMID 39207803 Get It

Abstract Background The authors previously developed an artificial intelligence (AI) to assist cytologists in the evaluation of digital whole‐slide images (WSIs) generated from bile duct brushing specimens. The aim of this trial was to assess the efficiency and accuracy of cytologists using a novel application with this AI tool. Methods Consecutive bile duct brushing WSIs from indeterminate strictures were obtained. A multidisciplinary panel reviewed all relevant information and provided a central interpretation for each WSI as being “positive,” “negative,” or “indeterminate.” The WSIs were then uploaded to the AI application. The AI scored each WSI as positive or negative for malignancy (i.e., computer‐aided diagnosis [CADx]). For each WSI, the AI prioritized cytologic tiles by the likelihood that malignant material was present in the tile. Via the AI, blinded cytologists reviewed all WSIs and provided interpretations (i.e., computer‐aided detection [CADe]). The diagnostic accuracies of the WSI evaluation via CADx, CADe, and the original clinical cytologic interpretation (official cytologic interpretation [OCI]) were compared. Results Of the 84 WSIs, 15 were positive, 42 were negative, and 27 were indeterminate after central review. The WSIs generated on average 141,950 tiles each. Cytologists using the AI evaluated 10.5 tiles per WSI before making an interpretation. Additionally, cytologists required an average of 84.1 s of total WSI evaluation. WSI interpretation accuracies for CADx (0.754; 95% CI, 0.622–0.859), CADe (0.807; 95% CI, 0.750–0.856), and OCI (0.807; 95% CI, 0.671–0.900) were similar. Conclusions This trial demonstrates that an AI application allows cytologists to perform a triaged review of WSIs while maintaining accuracy.
Visual pathology reports for improved collaboration at multidisciplinary head and neck tumor board
Fassler, Carly , Yalamanchi, Pratyusha , Aweeda, Marina , Rezk, Julie, Whitaker, Ryan, Rigsby, Ryan K. , Aulino, Joseph M., Hosokawa, Emily, Mehrad, Mitra , Ely, Kim, Lewis, James S. , Derman, Evan, LaHood, Ed, Sinard, Robert J. , Rosenthal, Eben L , Topf, Michael C , Murphy, Barbara, Lockney, Natalie A. , Rohde, Sarah L. , Rosenthal, Eben L. , Topf, Michael C.

Mayo Clinic

Head & Neck | August 29, 2024 | Volume: 47 | Issue: 2 | Pages: 452-462

10.1002/hed.27926 | PMID 39206523 Get It

AbstractPurposeMultidisciplinary tumor boards (TB) are the standard for discussing complex head and neck cancer cases. During TB, imaging and microscopic pathology is reviewed, but there is typically no visualization of the resected cancer.MethodsA pilot study was conducted to investigate the utility of visual pathology reports at weekly TB for 10 consecutive weeks. Faculty‐level participants completed a pre‐survey and post‐survey to assess understanding of resected cancer specimens.ResultsProviders (n = 25) across seven medical specialties completed pre‐survey and post‐survey. Following intervention, providers reported significant improvement in understanding of anatomic orientation of the specimen and sites of margin sampling (mean 47.4–96.1, p < 0.001), ability to locate the site of a positive margin (mean 69.5–91.1, p < 0.001), and confidence in treatment plans created (mean 69.5–89.2, p < 0.001) with the addition of visual pathology reports.ConclusionsVisual pathology reports improve provider understanding of resected cancer specimens at multidisciplinary TB.